Skip to content
10-Q

Quarterly Report

AVENUE THERAPEUTICS, INC. ATXI

0001437749-25-026935

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 12, 2025 3.18M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$1.36M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$5.37M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $3.33M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $2.59M
Stockholders Equity Q2 2025 · Jun 30, 2025 $4.06M
Stockholders Equity Q2 2025 · Dec 31, 2024 $2.8M
Current Liabilities Q2 2025 · Jun 30, 2025 $1.33M
Current Liabilities Q2 2025 · Dec 31, 2024 $816K
Total Liabilities Q2 2025 · Jun 30, 2025 $1.33M
Total Liabilities Q2 2025 · Dec 31, 2024 $816K
Total Assets Q2 2025 · Jun 30, 2025 $4.16M
Total Assets Q2 2025 · Dec 31, 2024 $2.67M
Sga Expense Q2 2025 · Jun 30, 2025 $915K
Sga Expense Q2 2025 · Jun 30, 2025 $2.41M
Sga Expense Q2 2025 · Jun 30, 2024 $1.46M
Sga Expense Q2 2025 · Jun 30, 2024 $2.78M
Rd Expense Q2 2025 · Jun 30, 2025 $192K
Rd Expense Q2 2025 · Jun 30, 2025 $603K
Rd Expense Q2 2025 · Jun 30, 2024 $1.36M
Rd Expense Q2 2025 · Jun 30, 2024 $3.75M
Net Income Q2 2025 · Jun 30, 2025 $335K
Net Income Q2 2025 · Jun 30, 2025 −$1.52M
Net Income Q2 2025 · Jun 30, 2024 −$2.69M
Net Income Q2 2025 · Jun 30, 2024 −$7.03M
Operating Income Q2 2025 · Jun 30, 2025 $297K
Operating Income Q2 2025 · Jun 30, 2025 −$1.61M
Operating Income Q2 2025 · Jun 30, 2024 −$2.82M
Operating Income Q2 2025 · Jun 30, 2024 −$6.53M
Revenue Q2 2025 · Jun 30, 2025 $1.4M
Revenue Q2 2025 · Jun 30, 2025 $1.4M
Revenue Q2 2025 · Jun 30, 2024 $0
Revenue Q2 2025 · Jun 30, 2024 $0